Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 58, showing 10 Applications out of 576 total, starting on record 211, ending on 220

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

211.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
25-04-2024 View

212.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
11-01-2024 View

213.

ECCT/24/10/01   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Videlis Nduba Nzioka
Site(s) in Kenya
1. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. University of Nairobi Clinical Research Centre (Nairobi City county)
 
21-12-2024 View

214.

ECCT/23/07/03   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Professor Videlis Nduba
2. Professor Videlis Nduba
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE-CENTRE FOR RESPIRATORY DISEASE RESEARCH (CRDR) (Nairobi City county)
2. KEMRI/CRDR, Siaya Clinical Research Annex (Siaya county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
6. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
7. University of Nairobi Clinical Research Centre (Nairobi City county)
 
19-11-2023 View

215.

ECCT/23/08/01   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Dr Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI-Mtwapa Clinical Annex (Kilifi county)
6. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
06-12-2023 View

216.

ECCT/26/02/03   REVIVE Study - KNH
    A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
 
28-09-2026 View

217.

ECCT/26/02/02   REVIVE Study - JOOTRH
    A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county)
 
22-08-2026 View

218.

ECCT/23/12/01   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Prof Walter Jaoko
2. Dr. Lucas Thina Otieno
3. Prof. Kariuki Simon
4. Dr. Janet Nyawira Oyieko
5. Walter Otieno
6. Onono Dr. Marcianah
7. Dr. Lucas Thina Otieno
8. Prof. Kariuki Simon
9. Dr. Janet Nyawira Oyieko
10. Walter Otieno
11. Onono Dr. Marcianah
Site(s) in Kenya
1. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
4. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
5. Siaya County Referral Hospital (SCRH (Siaya county)
6. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
02-05-2024 View

219.

ECCT/24/06/03   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Walter Otieno
Site(s) in Kenya
1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county)
 
20-09-2024 View

220.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
03-07-2024 View